JP2013533228A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533228A5
JP2013533228A5 JP2013513651A JP2013513651A JP2013533228A5 JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5 JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
solvate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013513651A
Other languages
English (en)
Japanese (ja)
Other versions
JP5791707B2 (ja
JP2013533228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/059300 external-priority patent/WO2011154359A1/de
Publication of JP2013533228A publication Critical patent/JP2013533228A/ja
Publication of JP2013533228A5 publication Critical patent/JP2013533228A5/ja
Application granted granted Critical
Publication of JP5791707B2 publication Critical patent/JP5791707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013513651A 2010-06-10 2011-06-06 新規アウリスタチン誘導体およびその使用 Active JP5791707B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10165550 2010-06-10
EP10165550.4 2010-06-10
EP11158464 2011-03-16
EP11158464.5 2011-03-16
PCT/EP2011/059300 WO2011154359A1 (de) 2010-06-10 2011-06-06 Neue auristatin-derivate und ihre verwendung

Publications (3)

Publication Number Publication Date
JP2013533228A JP2013533228A (ja) 2013-08-22
JP2013533228A5 true JP2013533228A5 (cg-RX-API-DMAC7.html) 2014-07-03
JP5791707B2 JP5791707B2 (ja) 2015-10-07

Family

ID=44275637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513651A Active JP5791707B2 (ja) 2010-06-10 2011-06-06 新規アウリスタチン誘導体およびその使用

Country Status (7)

Country Link
US (1) US8722629B2 (cg-RX-API-DMAC7.html)
EP (1) EP2579887B1 (cg-RX-API-DMAC7.html)
JP (1) JP5791707B2 (cg-RX-API-DMAC7.html)
CN (1) CN103200950B (cg-RX-API-DMAC7.html)
CA (1) CA2801971C (cg-RX-API-DMAC7.html)
ES (1) ES2528956T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011154359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621508B1 (de) 2010-09-29 2015-08-26 Seattle Genetics, Inc. N-carboxyalkyl-auristatine und ihre verwendung
CN103764667B (zh) * 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
CN103826661B (zh) * 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
JP2015505850A (ja) * 2011-12-14 2015-02-26 シアトル ジェネティックス, インコーポレイテッド 新規な抗体薬物コンジュゲート(adc)およびそれらの使用
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
WO2015095952A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Var2csa-drug conjugates
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
MY186711A (en) 2014-04-25 2021-08-12 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN108690119B (zh) * 2018-06-04 2022-04-19 莎穆(上海)生物科技有限公司 一种伊文思蓝修饰的多肽类前药及其制备和应用
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1999035164A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides
WO2000069472A2 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
CA2462653C (en) * 2001-11-07 2016-06-07 Aya Jakobovits Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US8343928B2 (en) * 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
RU2483080C2 (ru) 2006-10-27 2013-05-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применение
ES2523033T3 (es) 2008-03-18 2014-11-20 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
CN103826661B (zh) * 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途

Similar Documents

Publication Publication Date Title
JP2013533228A5 (cg-RX-API-DMAC7.html)
US11857522B2 (en) Compositions containing tucaresol or its analogs
JP2013540114A5 (cg-RX-API-DMAC7.html)
JP2020506951A5 (cg-RX-API-DMAC7.html)
JP2014515735A5 (cg-RX-API-DMAC7.html)
JP2017525730A5 (cg-RX-API-DMAC7.html)
JP2014510149A5 (cg-RX-API-DMAC7.html)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2012525393A5 (cg-RX-API-DMAC7.html)
JP2009536620A5 (cg-RX-API-DMAC7.html)
JP2010539110A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2020523388A5 (cg-RX-API-DMAC7.html)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
EP3890749A1 (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2015512943A5 (cg-RX-API-DMAC7.html)
JP2013533253A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
JP2013522368A5 (cg-RX-API-DMAC7.html)
US20230233557A1 (en) Formulations comprising heterocyclic protein kinase inhibitors
JPWO2023195529A5 (cg-RX-API-DMAC7.html)
JP2017525717A5 (cg-RX-API-DMAC7.html)
RU2001135802A (ru) Антагонисты рецептора брадикинина
JP2011518168A5 (cg-RX-API-DMAC7.html)